Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

6 terminated/withdrawn out of 16 trials

Success Rate

53.8%

-32.7% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

3 recruiting4 with results6 terminated

Enrollment Performance

Analytics

Phase 1

11(68.8%)

Phase 2

3(18.8%)

Phase 3

2(12.5%)

16Total

Phase 1(11)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT07278479Phase 1Recruiting

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Role: lead

NCT07036380Phase 2Recruiting

MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma

Role: collaborator

NCT04828161Phase 2Terminated

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

Role: collaborator

NCT05673057Phase 1Recruiting

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Role: lead

NCT05098405Phase 1Terminated

First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors

Role: lead

NCT05780463Phase 3Completed

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Role: collaborator

NCT04501978Phase 3Completed

ACTIV-3: Therapeutics for Inpatients With COVID-19

Role: collaborator

NCT03418532Phase 1Terminated

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Role: lead

NCT04049903Phase 1Completed

Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors

Role: lead

NCT04870164Phase 1Terminated

Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

Role: lead

NCT03084926Phase 1Completed

First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors

Role: lead

NCT04834856Phase 2Completed

Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

Role: lead

NCT03136653Phase 1Completed

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Role: lead

NCT02194426Phase 1Completed

First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients

Role: lead

NCT01042678Phase 1Terminated

Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema

Role: collaborator

NCT01086761Phase 1Terminated

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Role: collaborator

All 16 trials loaded